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ABSTRACT (word count = 299) 
Background: Guidelines recommend targeting systolic blood pressure (SBP)<130 mmHg in 
heart failure with preserved ejection fraction (HFpEF) with limited data.  
Objectives: To assess whether BP lowering is associated with clinical benefit, and whether the 
treatment effects of sacubitril/valsartan on outcomes are related to BP lowering, particularly 
among women who derive greater benefit from sacubitril/valsartan. 
Methods: We analyzed 4,795 participants from the Prospective Comparison of ARNI with ARB 
Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial. We related 
baseline and time-updated, mean achieved SBP quartiles (<120, 120-129, 130-139, ≥140 mmHg) 
to the primary outcome (CV death and total HF hospitalization), its components, myocardial 
infarction or stroke, and a renal composite outcome. At the 16-week visit, we assessed the 
relationship between SBP change and Kansas City Cardiomyopathy Questionnaire overall 
summary score (KCCQ-OSS) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). We 
analyzed whether the BP lowering effects of sacubitril/valsartan accounted for its treatment 
effects. 
Results: Average age was 73±8 years and 52% were women. After multivariable adjustment, 
baseline and mean achieved SBP 120-129mmHg demonstrated the lowest risk for all outcomes. 
Sacubitril/valsartan reduced SBP by 5.2 (95%CI: 4.4, 6.0) mmHg compared with valsartan at 4-
weeks, which was not modified by baseline SBP. However, sacubitril/valsartan reduced SBP 
more in women (6.3 mmHg) than men (4.0 mmHg) (interaction p=0.005). Change in SBP was 
directly associated with change in NT-proBNP (p<0.001) but not KCCQ-OSS (p=0.40). The 
association between sacubitril/valsartan and the primary outcome was not modified by baseline 
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SBP (interaction p=0.50) and was similar when adjusting for time-updated SBP, irrespective of 
sex.  
Conclusions: Baseline and mean achieved SBP of 120-129 mmHg identified the lowest risk 
HFpEF patients. Baseline SBP did not modify the treatment effect of sacubitril/valsartan and the 
BP lowering effects of sacubitril/valsartan did not account for its effects on outcomes, 
irrespective of sex. 
Keywords: heart failure with preserved ejection fraction; heart failure hospitalization; 
sacubitril/valsartan; blood pressure 
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CONDENSED ABSTRACT (word count = 100).  
Guidelines recommend targeting SBP<130mmHg in HFpEF, but the clinical benefits of, and 
influence of sacubitril/valsartan on, BP lowering are unknown. In PARAGON-HF, baseline and 
mean achieved SBP 120-129mmHg was associated with the lowest risk for adverse outcomes. 
Sacubitril/valsartan reduced SBP by 5.2mmHg compared with valsartan. The associations 
between sacubitril/valsartan and outcomes were not modified by baseline SBP and was similar 
when adjusting for time-updated SBP. In sum, SBP 120-129 mmHg identified the lowest risk 
patients, supporting current guidelines. Baseline SBP did not modify the treatment effect of 
sacubitril/valsartan and the BP lowering effects of sacubitril/valsartan did not account for its 
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ACRONYMS AND ABBREVIATIONS 
eGFR, estimated glomerular filtration rate 
HFpEF, heart failure with preserved ejection fraction  
KCCQ-OSS, Kansas City Cardiomyopathy Questionnaire overall summary score 
NT-proBNP, N-terminal pro B-type natriuretic peptide 
PARAGON-HF, Prospective Comparison of Angiotensin receptor–neprilysin inhibitor with 
Angiotensin-receptor blockers Global Outcomes in HF with Preserved Ejection Fraction  
PARAMOUNT, Prospective comparison of ARNi with ARB on Management Of heart failUre 
with preserved ejectioN fracTion 
SBP, systolic blood pressure 
SPRINT, Systolic Blood Pressure Intervention Trial  
TOPCAT, Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone 
Antagonist   
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INTRODUCTION  
Few therapeutic options exist in treating patients with heart failure with preserved 
ejection fraction (HFpEF), and accordingly, treatment has generally focused on optimizing 
management of comorbidities (1-4). Hypertension is very common in HFpEF, is thought to play 
an etiologic role, and because it leads to left ventricular hypertrophy, diastolic dysfunction, 
abnormal ventricular arterial coupling, and end organ damage, it has been conjectured that blood 
pressure control could relate to improvement in outcomes (5-7). In fact, professional society 
guidelines have recommended targeting a systolic blood pressure (SBP) of less than 130 mmHg 
in HFpEF (8,9). However, there is limited evidence to support this recommendation, particularly 
since the Systolic Blood Pressure Intervention Trial (SPRINT), which demonstrated that 
intensive versus standard BP control improved cardiovascular outcomes, excluded patients with 
symptomatic HF (10). In addition, while several agents that lower BP have been studied in 
clinical trials of HFpEF (1-3,11,12), a dedicated trial using BP targets has not been performed in 
this population. Further, a substudy of Treatment of Preserved Cardiac Function Heart Failure 
with an Aldosterone Antagonist (TOPCAT) Americas did not identify a significant relationship 
between SBP quartiles and cardiovascular outcomes, and blood pressure reduction did not 
explain the potential beneficial effects of spironolactone (13).  
Thus, the extent to which SBP control influences clinical outcomes remains unclear. In 
addition, whether BP reduction is associated with clinical benefit (reflected by quality of life and 
cardiovascular outcomes) is of significant interest. Moreover, the relationship between BP 
reduction and biomarkers in HFpEF is not well established. The Prospective Comparison of 
ARNI [angiotensin receptor–neprilysin inhibitor] with ARB [angiotensin-receptor blockers] 
Global Outcomes in HF with Preserved Ejection Fraction (PARAGON-HF) trial is the largest 
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randomized study in HFpEF to date (12), and whether the anti-hypertensive effects of 
sacubitril/valsartan mediate its effects on outcomes, particularly among women and those with 
lower EF given significant effect modification observed in these subgroups, is unknown (14,15).  
In this study, we assessed the prognostic role of baseline SBP and mean achieved SBP in 
patients with HFpEF enrolled in PARAGON-HF, the relationship between SBP lowering with 
biomarker and clinical outcomes, and whether the SBP lowering effect of sacubitril-valsartan 
related to its treatment effects. We hypothesized that the relationship between SBP and outcomes 
would be J-shaped (13), and the SBP lowering effect of sacubitril-valsartan would not be 
responsible for its treatment effects.  
 
METHODS 
PARAGON-HF study design 
The design of the PARAGON-HF study has been described in detail previously (5). 
Briefly, PARAGON-HF was an international, randomized, double blind, parallel group, actively-
controlled, 2-arm event-driven trial comparing the efficacy and safety of sacubitril/valsartan 
versus valsartan in patients with HFpEF. PARAGON-HF enrolled patients with signs and 
symptoms of heart failure (New York Heart Association class II–IV), left ventricular EF ≥45%, 
increased plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) 
(degree of elevation depending on history of HF hospitalization within 9 months and presence or 
absence of atrial fibrillation on screening electrocardiogram), evidence of structural heart disease 
(increased left atrial size or left ventricular hypertrophy), and diuretic therapy within 30 days. 
Before randomization, patients entered sequential single-blind run-in periods ensuring that both 
treatments were tolerated at half the target doses. The primary endpoint for the trial was 
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cardiovascular death and total (first and recurrent) HF hospitalizations. The study was approved 
by institutional review boards at individual study sites, and all patients signed written informed 
consent.  
Key exclusion criteria included prior left ventricular EF <40%, and SBP <110 or ≥180 
mm Hg. Patients with SBP >150 mm Hg were excluded unless they were receiving at least 3 
antihypertensive medications at screening. In addition, participants were excluded with estimated 
glomerular filtration rates (eGFR) <30 ml/min/1.73 m2 as calculated by the Modification in Diet 
in Renal Disease formula at visit 1. Detailed exclusion criteria are listed elsewhere (5). For the 
present study, we excluded 1 participant with missing SBP at baseline and 26 participants 
enrolled from a site closed for violations of Good Clinical Practice. 
 
Study Outcomes 
Endpoints studied in this analysis include the primary composite outcome of total (first 
and recurrent) hospitalizations for HF and death from cardiovascular causes, total HF 
hospitalizations, cardiovascular death, myocardial infarction or stroke, all-cause mortality, and a 
renal composite outcome (decrease in the eGFR of ≥50%, development of end-stage renal 
disease, or death due to renal failure and doubling of serum creatinine). For safety assessment, 
we analyzed dose reduction or discontinuation. Among a subgroup of participants with available 
data, we also assessed the relationship of the change in SBP to several endpoints included at the 
16-week visit. These included quality of life assessed using the overall summary score on the 
Kansas City Cardiomyopathy Questionnaire (KCCQ-OSS) (scores range from 0 to 100, with 
higher scores indicating better health status) (16), NT-proBNP, and high-sensitivity troponin T.  
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Statistical analysis 
Baseline characteristics grouped by quartiles (<120, 120-129, 130-139, ≥140 mmHg) of 
baseline SBP were described using means±SD and medians and interquartile ranges or 
percentages as appropriate for the levels of measurement and distributions of the variables. These 
quartiles also approximated clinical guideline thresholds for classification and treatment of 
hypertension (9). The SBP quartiles were compared using ANOVA for continuous variables and 
chi-squared tests (or Fisher’s exact test when appropriate) for categorical variables.  
The association between baseline SBP quartiles and the efficacy and safety outcomes 
were assessed using crude and multivariable-adjusted Cox regression, using the 2nd quartile (120-
129mmHg) as the referent group (with the lowest event rate), given a J-shaped relationship 
observed. In a complementary analysis using restricted cubic splines, we examined the 
continuous association between SBP and all outcomes. Four knots placed at the 5th, 35th, 65th, 
and 95th percentiles were used for all outcomes except the renal composite outcome, which was 
analyzed linearly. Multivariable models adjusted for covariates used in a previous analysis of 
SBP in HFpEF, including region, atrial fibrillation, creatinine, diabetes mellitus, New York 
Heart Association class, heart rate, sex, age, race, current smoking, peripheral vascular disease, 
number of anti-hypertensive medications, and treatment group (model 1) (13). We additionally 
adjusted for diastolic blood pressure in model 2. We repeated these analyses using mean SBP as 
a time-updated covariate, which was updated at each BP ascertainment to represent the average 
observed blood pressure up to that time point (17).  
We next determined the valsartan-adjusted change in SBP from baseline to the 4-week 
visit overall and by SBP quartile. Four weeks was selected as this was the time at which maximal 
SBP change occurred in the trial (12). Interaction terms between treatment and both gender and 
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EF (modeled continuously) were tested (14,15). We subsequently assessed the relationships 
between change in SBP (expressed per 10 mmHg reduction) from baseline to the 16 and 48-
week visits with KCCQ-OSS score, log transformed NT-proBNP, and log transformed high-
sensitivity troponin T. An interaction term between treatment and continuous SBP was tested. 
To understand whether SBP reduction related to the treatment effect of 
sacubitril/valsartan, we generated Cox models assessing the relationship between treatment 
assignment and outcomes adjusting for baseline SBP and time-updated SBP (which was updated 
at each study visit). Interaction analyses were performed to determine whether sex or EF 
(modeled continuously) modified these relationships. We assessed the primary outcome, 
recurrent HF hospitalization, and the renal composite outcome since these outcomes were most 
strongly associated with a treatment effect (12). Analyses were performed using STATA version 
14, and a two-sided p-value < 0.05 was considered statistically significant. 
 
RESULTS 
Baseline characteristics  
 The baseline characteristics of the 4,795 participants meeting study inclusion criteria 
stratified by quartiles of SBP are shown in Table 1. The mean baseline BP was 131±15 / 74±11 
mmHg. The average age was 73±8 years, 52% were women, and 82% were white. Higher SBP 
quartile was associated with higher diastolic BP, proportionately more people of white race, 
higher body mass index, lower heart rate, less frequent atrial fibrillation, more frequent diabetes 
mellitus, higher eGFR, and lower NT-proBNP (p<0.05 for all comparisons).  
In crude analyses of the efficacy outcomes, using quartile 2 (120-129mmHg) as the 
referent quartile, both the lowest and highest quartiles had a higher risk of the primary outcome 
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(Table 2). However, after multivariable adjustment, only the highest quartile was independently 
associated with elevated risk for the primary outcome (HR 1.54, 95% CI 1.24, 1.91), which was 
driven by a greater risk in total HF hospitalizations (HR 1.63, 95% CI 1.28, 2.09). Quartile 2 
demonstrated the lowest risk for myocardial infarction or stroke, with greater risk observed in 
each of the other 3 quartiles after multivariable adjustment. Risk for the renal composite outcome 
increased in a graded fashion with increasing SBP quartile, while the risk for drug 
discontinuation was elevated at both the lowest and highest SBP quartiles after adjustment. Thus, 
quartile 2 demonstrated the lowest risk for all studied outcomes.  
In a complementary analysis modeling SBP as a continuous variable, a J-shaped 
relationship was observed between SBP and the primary outcome (as well as the other 
cardiovascular outcomes) (Figure 1); p<0.05 for overall relationship and for non-linearity). 
Baseline SBP did not modify the relationship between sacubitril/valsartan and the primary 
outcome (interaction p=0.50) or any other outcome (p>0.20 for all interaction terms).  
To understand the relationship between change in BP and subsequent risk, we analyzed 
the relationship between time-updated, mean achieved SBP for all study outcomes, using quartile 
2 (120-129mmHg) as the referent arm (Table 3) (17). Similar to the baseline SBP analysis, 
quartile 4 was associated with higher risks of the primary outcome and recurrent HF 
hospitalization after multivariable adjustment. In contrast, compared to quartile 2, quartile 1 was 
associated with a higher risk of mortality (HR 1.29, 95% CI 1.04, 1.62), and both quartiles 3 and 
4 were associated with a higher risk of myocardial infarction or stroke as well as the renal 
composite outcome. Therefore quartile 2 was again associated with the lowest risk for all 
outcomes.  
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During the run-in period, SBP decreased 5.5 (95% CI 5.1, 6.0) mmHg. After 
randomization, sacubitril/valsartan further reduced SBP by a maximum of 5.2 (95% CI 4.4, 6.0) 
mmHg, when compared with valsartan, by the 4-week visit (Table 4). Sacubitril/valsartan had a 
similar BP lowering effect across the 4 SBP baseline quartiles at the 4-week visit (interaction 
p=0.61) (Table 4 and CENTRAL ILLUSTRATION). However, during follow-up, the 
difference in SBP among the treatment arms in the highest quartile diminished over time. In 
addition, the distribution of time-updated, mean achieved SBP quartile for the entire cohort is 
shown at randomization, 16 weeks, and 48 weeks by treatment arm in Figure 3, demonstrating a 
greater distribution of participants in lower SBP categories in the sacubitril/valsartan arm 
compared to the valsartan arm; this distribution is also shown in Supplementary Table 1 among 
those with baseline SBP ≥130 mmHg.  
We noted significant effect modification by gender for the SBP lowering effect of 
sacubitril/valsartan, such that sacubitril/valsartan reduced SBP at the 4-week visit more in 
women (6.3 mmHg, 95% CI 5.2, 7.4 mmHg) than in men (4.0 mmHg, 95% CI 2.9, 5.1 mmHg) 
(interaction p=0.005), which was driven by higher SBP among women in the valsartan arm 
(Figure 4). A marginal treatment effect by EF was observed (interaction p=0.08), such that 
sacubitril/valsartan reduced SBP more in with EF>57% (5.8 mmHg, 95% CI 4.6, 7.0 mmHg) 
than in those with EF≤57% (4.6 mmHg, 95% CI 3.6, 5.7 mmHg). 
In a mechanistic analysis, we assessed the relationship between change in SBP between 
baseline to the 16 and 48-week visits with quality of life (KCCQ-OSS) and biomarkers (NT-
proBNP and high-sensitivity troponin T) (Table 5). Change in SBP was not associated with 
change in KCCQ-OSS or high-sensitivity troponin T after multivariable adjusted analysis. 
Change in SBP was associated with a modest change in log transformed NT-proBNP after 
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multivariable (-3.8% per 10 mmHg lowering in SBP, p<0.001) analysis at 16 weeks, which was 
similar at 48 weeks (-2.1% per 10 mmHg lowering in SBP, p=0.027).  
To determine whether the treatment effects of sacubitril/valsartan were mediated by BP 
reduction, we performed Cox regression adjusting for baseline SBP and time-updated SBP for 
the primary outcome, recurrent HF hospitalization, and the renal composite outcome. As shown 
in Table 6, adjustment had little effect on the hazard ratios for any endpoint. Further, analyses 
were consistent regardless of sex (interaction p=0.49) or EF (continuous interaction p=0.80). 
 
DISCUSSION 
In patients with HFpEF, both baseline and time-updated, mean achieved SBP 120-129 
mmHg independently identified patients at the lowest risk for cardiovascular and renal outcomes 
prespecified in PARAGON-HF. Change in SBP related to change in NT-proBNP, though not 
with quality of life. Sacubitril/valsartan reduced SBP by a maximum of 5.2 mmHg, compared 
with valsartan, by the 4-week visit; this effect was consistently observed across baseline SBP 
quartiles, though the BP lowering effect was greater in women than men. However, the treatment 
effect of sacubitril/valsartan was not modified by baseline SBP and was independent of change 
in SBP, irrespective of sex. Our analyses provide new insight into the relationship of baseline, 
and mean achieved, SBP and outcomes in HFpEF, and further suggest that SBP reduction with 
sacubitril/valsartan is not responsible for its treatment benefits in HFpEF in both women and 
men. 
A lack of a relationship between SBP quartiles and outcomes in HFpEF was shown in a 
TOPCAT analysis restricted to the Americas, though when SBP was analyzed continuously, a J-
shaped relationship was observed (13). This difference in SBP quartile findings relative to the 
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current study may simply relate to the significantly larger sample size in PARAGON. 
Additionally, in a post-hoc analysis of the Prospective comparison of ARNI with ACEI to 
Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial, a 
randomized trial of sacubitril/valsartan in HF and reduced EF, the relationship between SBP and 
several outcomes was also noted to be J-shaped (18). Low SBP in HFpEF could be causally 
related to worse outcomes, but might also signify a sicker patient population with confounding 
conditions, supported by attenuation of the association between lower SBP and worse outcomes 
after the multivariable adjustment which included comorbidities and other variables predictive of 
higher risk. For example, there was a higher percentage of patients with atrial fibrillation or 
flutter in the lowest SBP quartile, as demonstrated in another HFpEF analysis (13), which could 
reflect greater use of therapies for rate control that additionally lower SBP or loss of atrial 
contraction that could also reduce BP. 
 The anti-hypertensive properties of sacubitril/valsartan in HFpEF in PARAGON-HF are 
similar to findings observed in HF with reduced EF. Vasodilators including sacubitril/valsartan 
in PARADIGM-HF (though not hydralazine and nitrates), reduce SBP across the baseline SBP 
range (18-21). Similar to these former studies in HFrEF, the beneficial effects of the therapies 
tested were independent of baseline SBP or change in SBP in PARAGON-HF. Among HFpEF 
patients, the BP lowering of sacubitril-valsartan in PARAGON-HF is similar in magnitude to 
spironolactone in TOPCAT (13). Compared specifically to studies of sacubitril-valsartan in other 
settings, the magnitude of BP reduction observed in PARAGON-HF was greater than that seen 
in mild to moderate hypertension (22) and acutely decompensated HFrEF (23), but similar to 
chronic kidney disease (24), HFrEF (18), and the phase II trial of sacubitril-valsartan in HFpEF 
(25). Interestingly, women achieved greater SBP reduction than men, which was driven by worse 
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BP control with valsartan and equivalent BP control with sacubitril/valsartan compared to men. 
This differential gender effect does not appear to be observed in other cardiovascular conditions 
for which valsartan has been studied (26). However, the BP lowering effect still failed to explain 
the beneficial treatment effect of sacubitril/valsartan observed in women (14). In addition, a 
marginal treatment interaction by EF was observed, such that those with lower baseline EF had 
less BP reduction. It is possible the physiology in these participants behave more similarly to 
HFrEF, whereby some vasodilators may increase cardiac output, attenuating the BP lowering 
effects of therapy (19,21). 
In a mechanistic analysis, we assessed the change in SBP with change in biomarkers and 
quality of life. Change in SBP was associated with change in NT-proBNP, but not high-
sensitivity troponin T or quality of life. Interestingly, the phase II trial of ARNI in HFpEF did 
not identify a significant relationship between change in BP and change in NT-proBNP (25). Our 
findings of a modest relationship may relate to larger sample or larger range of SBP allowed for 
study entry in PARAGON-HF. The lack of change with other high sensitivity troponin T and 
quality of life could reflect a longer time course needed to achieve these findings.  
As a result of the SPRINT Trial, professional society guidelines have recommended an 
SBP goal <130 mmHg (8). Notably, SPRINT excluded patients with prevalent HF. Our analysis 
shows that a mean achieved SBP of 120-129 mmHg was associated with the lowest risk for all 
study outcomes, supporting the current recommendation for blood pressure management. Given 
the observational nature of this analysis, a randomized trial of achieved SBP targets in HFpEF 
would be useful to confirm these findings.  
Interestingly, the SBP reduction of sacubitril/valsartan in PARAGON-HF did not account 
for the treatment effect of sacubitril/valsartan (irrespective of sex), similar to findings of 
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spironolactone in HFpEF (13). It is possible that the time course needed for BP reduction to 
reflect in the treatment effect could be much longer, since a longer duration of BP control may 
improve arterial stiffness, diastolic function, or cardiac remodeling. In addition, greater SBP 
control in the valsartan arm over time, particularly evident in the highest quartile, may have 
diminished the relevance of SBP reduction to the treatment effect. The Prospective comparison 
of ARNI with ARB on Management of HFpEF (PARAMOUNT) trial also demonstrated the 
independence of sacubitril/valsartan BP lowering with left atrial size and NYHA class (25). In 
addition, in HFrEF, sacubitril/valsartan did not affect central aortic stiffening compared to 
enalapril (27). These data suggest that the potential benefits of sacubitril/valsartan in HFpEF are 
likely multifactorial and go beyond its hemodynamic effects on blood pressure. 
Sacubitril/valsartan, for instance, increases availability of natriuretic peptides and a number of 
other vasoactive peptides which induce diuresis, natriuresis, and improve myocardial relaxation 
(5). Sacubitril/valsartan also specifically improves left atrial remodeling, a strong predictor of 
adverse events in HFpEF (28).  
There are some limitations of the study. Ambulatory BP monitoring, rather than office 
BPs, may provide a more accurate assessment of BP as well as the treatment effect of 
sacubitril/valsartan. A previous analysis of sacubitril/valsartan in hypertension showed a 
significant reduction in ambulatory BP (29), but its relationship to outcomes was not studied. In 
addition, the specific inclusion/exclusion criteria for blood pressure in PARAGON-HF may limit 
generalizability to a broad HFpEF population. Finally, although PARAGON-HF is the largest 
trial in HFpEF to date, we may have been underpowered to detect more subtle relationships of 
SBP quartiles with some outcomes, particularly in subgroups.  
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In summary, baseline and mean achieved SBP of 120-129 mmHg was associated with the 
lowest risk of adverse outcomes after multivariable adjustment. Lowering SBP was associated 
with a modest reduction in NT-proBNP, however without relationship to quality of life. 
Sacubitril/valsartan consistently reduced SBP across baseline SBP quartiles by 5.2 mmHg, an 
effect greater in women than men at the 4-week visit compared to valsartan. though BP reduction 
failed to account for its treatment effects on cardiovascular outcomes irrespective of sex. The 
potential benefits of sacubitril/valsartan in HFpEF may thus be mediated through other 
mechanisms.  
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PERSPECTIVES 
Competency in Medical Knowledge: In patients with heart failure with preserved ejection 
fraction (HFpEF), a systolic blood pressure (SBP) of 120-129 mmHg identified the lowest risk 
participants. Sacubitril/valsartan lowers blood pressure by ~5 mmHg compared to valsartan in 
HFpEF, an effect greater among women than men.   
Competency in Patient Care: Our findings support current professional society guidelines for 
targeting SBP<130 mmHg in patients with HFpEF and reinforce the current focus toward 
optimal BP management in HFpEF. Women may derive a greater SBP lowering effect with 
sacubitril/valsartan compared to valsartan. 
Translational Outlook: Since SBP lowering failed to explain the treatment effects of 
sacubitril/valsartan, future research into mechanisms of potential benefit are needed.  
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FIGURE LEGENDS 
Figure 1:  
Title: Relationship between Baseline Continuous Systolic Blood Pressure and Efficacy and 
Safety Outcomes 
Caption: Incidence rates for the primary endpoint, cardiovascular death, total heart failure 
hospitalization, all-cause death, myocardial infarction or stroke, a renal composite outcome, and 
study drug dose reduction or discontinuation among all patients according to systolic blood 
pressure at baseline. Sacubitril/valsartan shown in red, and valsartan depicted in blue. The 
interrupted lines are 95% confidence limits. MI, myocardial infarction; p-yrs, person-years. 
Figure 2 (CENTRAL ILLUSTRATION):  
Title: Treatment effects of systolic blood pressure over time by baseline systolic blood pressure 
quartile . 
Caption: Systolic blood pressure during follow-up for valsartan (blue) and sacubitril/valsartan 
(red) treated patients shown separately for each systolic blood pressure quartile at baseline. Visits 
are truncated after week 216. Bars represent 95% confidence interval. SBP, systolic blood 
pressure.  
Figure 3:  
Title: Stacked bar graphs of time-updated, mean achieved systolic blood pressure quartile over 
time by treatment group. 
Caption: Percent of participants in each time-updated, mean achieved systolic blood pressure 
quartile at randomization, 16-week, and 48-week visits by treatment randomization to valsartan 
or sacubitril/valsartan. Systolic blood pressure expressed in mmHg.  
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Figure 4:  
Title: Systolic blood pressure over time by treatment arm and gender. 
Caption: Women (maroon) had higher blood pressure than men (navy) on valsartan treatment, 
but there was no gender difference in patients randomized to sacubitril/valsartan. Visits are 
truncated after week 216. Bars represent 95% confidence interval. SBP, systolic blood pressure.  
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SBP (mmHg) 112  ± 5 124  ± 3 133  ± 3 149  ± 10  
DBP (mmHg) 67   ± 9 73   ± 9 76   ± 9 79   ± 11 <0.001 
Pulse pressure (mmHg) 44   ± 9 50   ± 10 57   ± 9 70   ± 14 <0.001 
Randomization to 
sacubitril/valsartan, n (%) 584     (51.0%) 537     (48.6%) 582     (50.4%) 704     (50.7%) 0.86 
Age, years 73   ± 9 73   ± 8 72   ± 8 73   ± 8 0.52 
Female sex, n (%) 574     (50.1%) 554     (50.1%) 610     (52.8%) 741     (53.3%) 0.05 
White race, n (%) 879     (76.7%) 913     (82.6%) 942     (81.6%) 1173    (84.4%) <0.001 
NYHA, n (%)     0.18 
   I 33      (2.9 %) 33      (3.0 %) 23      (2.0 %) 48      (3.5 %)  
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   II 877     (76.6%) 851     (77.0%) 889     (77.0%) 1088    (78.3%)  
   III 229     (20.0%) 219     (19.8%) 235     (20.4%) 249     (17.9%)  
   IV 6       (0.5 %) 2       (0.2 %) 7       (0.6 %) 4       (0.3 %)  
Geographic region, n (%)     0.33 
   Asia-Pacific or other 238     (20.8%) 163     (14.8%) 173     (15.0%) 188     (13.5%)  
   Central Europe 274     (23.9%) 392     (35.5%) 502     (43.5%) 547     (39.4%)  
   Latin America 91      (7.9 %) 92      (8.3 %) 94      (8.1 %) 93      (6.7 %)  
   North America 209     (18.2%) 124     (11.2%) 100     (8.7 %) 126     (9.1 %)  
   Western Europe 334     (29.1%) 334     (30.2%) 286     (24.8%) 435     (31.3%)  
KCCQ-OSS 70.6 ± 19.5 71.8 ± 18.6 71.6 ± 19.1 71.6 ± 18.7 0.26 
Physical Characteristics      
     Body mass index (kg/m2) 29.9 ± 5.2 30.1 ± 4.9 30.3 ± 5.0 30.5 ± 4.9 0.001 
     Heart rate (beats/min) 71.4 ± 12.8 70.8 ± 12.3 70.4 ± 11.7 69.5 ± 12.2 <0.001 
Selvaraj S, et al. Systolic Blood Pressure in HFpEF   31 
 
Comorbidities, n (%)      
     Hypertension 1038    (90.6%) 1053    (95.3%) 1122    (97.1%) 1370    (98.6%) <0.001 
     Hospitalization for HF 546     (47.6%) 526     (47.6%) 577     (50.0%) 657     (47.3%) 0.91 
     Atrial fibrillation or flutter 480     (41.9%) 394     (35.8%) 346     (30.1%) 332     (24.0%) <0.001 
     Diabetes mellitus 424     (37.0%) 461     (41.7%) 507     (43.9%) 669     (48.2%) <0.001 
     Myocardial infarction 261     (22.8%) 241     (21.8%) 265     (22.9%) 316     (22.8%) 0.84 
     Stroke 112     (9.8 %) 116     (10.5%) 133     (11.5%) 147     (10.6%) 0.42 
     Current smoker 90      (7.9 %) 78      (7.1 %) 87      (7.6 %) 98      (7.1 %) 0.55 
Medication Use, n (%)      
     ACE-I and/or ARB at screening 921     (80.4%) 948     (85.8%) 1006    (87.1%) 1264    (91.0%) <0.001 
     Beta-blocker 907     (79.1%) 886     (80.2%) 931     (80.6%) 1096    (78.9%) 0.89 
     Calcium channel blocker 275     (24.0%) 368     (33.3%) 414     (35.8%) 583     (42.0%) <0.001 
     Diuretic 1088    (94.9%) 1062    (96.1%) 1114    (96.5%) 1320    (95.0%) 0.92 
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     Mineralocorticoid antagonist 340     (29.7%) 305     (27.6%) 304     (26.3%) 290     (20.9%) <0.001 
Laboratory Testing      
     Estimated glomerular filtration 
rate (mL/min/1.78 m2) 60   ± 18 62   ± 19 64   ± 19 64   ± 20 <    0.001 
     Hemoglobin (mg/dL) 13.5 ± 1.6 13.5 ± 1.5 13.5 ± 1.6 13.5 ± 1.6 0.97 
     NT-proBNP (pg/mL)* 1028 [544, 
1680] 918 [466, 1598] 852 [432, 1660] 790 [446, 1556] <0.001 
LV Ejection Fraction 58   ± 8 58   ± 8 57   ± 8 58   ± 8 0.16 
*Presented as median [25th-75th percentile] since values are skewed.  
NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; KCCQ-OSS, Kansas City Cardiomyopathy Questionnaire 
Overall Summary Score; ACE-I, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; HF, heart failure; LV, left ventricular; NT-
proBNP, N-terminal pro-B-type natriuretic peptide. 
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TABLE 2. Event Rates and Crude and Adjusted Hazard Ratios for Efficacy and Safety Outcomes by Baseline Systolic Blood 
Pressure Quartile 











Composite endpoint     
● Event rate and 95% CI 
(per 100 person-years) 
15.2 (13.2, 17.6) 11.4 (9.7, 13.5) 12.2 (10.6, 14.1) 15.6 (13.6, 17.8) 
● Crude model HR (95% 
CI) 
1.34 (1.08, 1.67) Ref 1.07 (0.86, 1.34) 1.37 (1.10, 1.69) 
● Multivariable adjusted 
model 1 HR (95% CI) 
1.18 (0.94, 1.47) Ref 1.17 (0.94, 1.46) 1.43 (1.16, 1.77) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.11 (0.89, 1.39) Ref 1.21 (0.98, 1.51) 1.54 (1.24, 1.91) 
Cardiovascular mortality     
● Event rate and 95% CI 
(per 100 person-years) 
3.5 (2.9, 4.3) 2.6 (2.1, 3.3) 3.0 (2.5, 3.6) 2.9 (2.4, 3.4) 
Selvaraj S, et al. Systolic Blood Pressure in HFpEF   34 
 
● Crude model HR (95% 
CI) 
1.35 (1.02, 1.79) Ref 1.13 (0.85, 1.51) 1.08 (0.82, 1.43) 
● Multivariable adjusted 
model HR (95% CI) 
1.24 (0.93, 1.65) Ref 1.16 (0.87, 1.55) 1.17 (0.88, 1.55) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.18 (0.88, 1.58) Ref 1.19 (0.89, 1.60) 1.23 (0.92, 1.65) 
Recurrent HF hospitalization     
● Event rate and 95% CI 
(per 100 person-years) 
11.7 (9.9, 13.8) 8.8 (7.2, 10.6) 9.2 (7.8, 10.9) 12.7 (10.9, 14.8) 
● Crude model HR (95% 
CI) 
1.34 (1.04, 1.72) Ref 1.06 (0.82, 1.36) 1.45 (1.14, 1.86) 
● Multivariable adjusted 
model HR (95% CI) 
1.17 (0.91, 1.51) Ref 1.18 (0.91, 1.51) 1.51 (1.18, 1.92) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.10 (0.85, 1.42) Ref 1.22 (0.95, 1.57) 1.63 (1.28, 2.09) 
Myocardial infarction or stroke     
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● Event rate and 95% CI 
(per 100 person-years) 
3.3 (2.7, 4.0) 1.9 (1.5, 2.5) 3.0 (2.5, 3.7) 3.7 (3.1, 4.3) 
● Crude model HR (95% 
CI) 
1.70 (1.24, 2.33) Ref 1.56 (1.31, 2.15) 1.88 (1.39, 2.54) 
● Multivariable adjusted 
model HR (95% CI) 
1.53 (1.10, 2.12) Ref 1.66 (1.20, 2.30) 1.98 (1.45, 2.70) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.54 (1.10, 2.15) Ref 1.66 (1.20, 2.30) 1.97 (1.43, 2.70) 
All-cause mortality     
● Event rate and 95% CI 
(per 100 person-years) 
5.8 (5.1, 6.7) 5.0 (4.3, 5.8) 4.5 (3.9, 5.3) 4.7 (4.1, 5.4) 
● Crude model HR (95% 
CI) 
1.19 (0.96, 1.46) Ref 0.91 (0.73, 1.14) 0.93 (0.76, 1.15) 
● Multivariable adjusted 
model HR (95% CI) 
1.12 (0.90, 1.39) Ref 0.95 (0.76, 1.19) 1.00 (0.80, 1.23) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.07 (0.86, 1.33) Ref 0.97 (0.78, 1.22) 1.05 (0.84, 1.31) 
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Renal composite outcome     
● Event rate and 95% CI 
(per 100 person-years) 
0.3 (0.2, 0.6) 0.5 (0.3, 0.8) 0.8 (0.5, 1.1) 1.1 (0.9, 1.5) 
● Crude model HR (95% 
CI) 
0.67 (0.30, 1.49) Ref 1.67 (0.88, 3.15) 2.44 (1.37, 4.38) 
● Multivariable adjusted 
model HR (95% CI) 
0.63 (0.28, 1.41) Ref 1.74 (0.92, 3.29) 2.47 (1.37, 4.43) 
● Multivariable adjusted 
model 2 HR (95% CI) 
0.60 (0.27, 1.37) Ref 1.77 (0.93, 3.36) 2.58 (1.42, 4.71) 
Drug discontinuation     
● Event rate and 95% CI 
(per 100 person-years) 
11.8 (10.6, 13.1) 8.8 (7.8, 10.0) 8.7 (7.8, 9.9) 10.7 (9.7, 11.8) 
● Crude model HR (95% 
CI) 
1.34 (1.14, 1.57) Ref 0.99 (0.83, 1.18) 1.21 (1.03, 1.42) 
● Multivariable adjusted 
model HR (95% CI) 
1.27 (1.08, 1.50) Ref 1.04 (0.87, 1.23) 1.23 (1.04, 1.45) 
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● Multivariable adjusted 
model 2 HR (95% CI) 
1.28 (1.09, 1.52) Ref 1.03 (0.87, 1.23) 1.22 (1.03, 1.44) 
HR, hazard ratio; CI, confidence interval; HF, heart failure. 
Model 1 covariates include region, atrial fibrillation, creatinine, diabetes mellitus, New York Heart Association class, heart rate, sex, age, race, 
current smoking, number of anti-hypertensive medications, and treatment group.  
Model 2 includes model 1 covariates and additionally adjusts for diastolic blood pressure.  
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TABLE 3. Event Rates and Crude and Adjusted Hazard Ratios for Efficacy and Safety Outcomes by Time-Updated Mean 
Achieved Systolic Blood Pressure Quartile 








Composite endpoint     
● Events/person-years 397/2564 474/3776 499/4013 532/3494 
● Event rate and 95% CI 
(per 100 person-years) 
15.5 (14.0, 17.1) 12.6 (11.5, 13.7) 12.4 (11.4, 13.6) 15.2 (14.0, 16.6) 
● Crude model HR (95% 
CI) 
1.25 (1.04, 1.42) Ref 0.99 (0.87, 1.12) 1.22 (1.07, 1.38) 
● Multivariable adjusted 
model 1 HR (95% CI) 
1.10 (0.96, 1.27) Ref 1.05 (0.92, 1.19) 1.24 (1.10, 1.41) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.07 (0.93, 1.23) Ref 1.07 (0.94, 1.22) 1.30 (1.14, 1.47) 
Cardiovascular mortality     
● Events/person-years 89/2559 112/3780 117/4015 98/3505 
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● Event rate and 95% CI 
(per 100 person-years) 
3.5 (2.8, 4.3) 3.0 (2.5, 3.6) 2.9 (2.4, 3.5) 2.8 (2.3, 3.4) 
● Crude model HR (95% 
CI) 
1.20 (0.91, 1.58) Ref 0.98 (0.76, 1.27) 0.95 (0.72, 1.24) 
● Multivariable adjusted 
model HR (95% CI) 
1.15 (0.86, 1.53) Ref 1.01 (0.78, 1.31) 1.01 (0.77, 1.34) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.12 (0.84, 1.50) Ref 1.03 (0.79, 1.34) 1.05 (0.79, 1.39) 
Recurrent HF hospitalization     
● Events/person-years 312/2564 356/3776 385/4013 433/3494 
● Event rate and 95% CI 
(per 100 person-years) 
12.2 (10.9, 13.6) 9.4 (8.5, 10.5) 9.6 (8.7, 10.6) 12.4 (11.3, 13.6) 
● Crude model HR (95% 
CI) 
1.30 (1.12, 1.51) Ref 1.02 (0.88, 1.18) 1.32 (1.14, 1.51) 
● Multivariable adjusted 
model HR (95% CI) 
1.13 (0.97, 1.32) Ref 1.09 (0.94, 1.26) 1.33 (1.15, 1.54) 
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● Multivariable adjusted 
model 2 HR (95% CI) 
1.09 (0.94, 1.28) Ref 1.11 (0.96, 1.29) 1.39 (1.20, 1.60) 
Myocardial infarction or stroke     
● Events/person-years 78/2467 84/3647 116/3857 125/3318 
● Event rate and 95% CI 
(per 100 person-years) 
3.2 (2.5, 3.9) 2.3 (1.9, 2.9) 3.0 (2.5, 3.6) 3.8 (3.2, 4.5) 
● Crude model HR (95% 
CI) 
1.33 (0.98, 1.82) Ref 1.31 (0.98, 1.73) 1.62 (1.23, 2.14) 
● Multivariable adjusted 
model HR (95% CI) 
1.21 (0.87, 1.66) Ref 1.39 (1.05, 1.85 1.70 (1.28, 2.25) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.21 (0.88, 1.69) Ref 1.39 (1.04, 1.84) 1.68 (1.26, 2.24) 
All-cause mortality     
● Events/person-years 161/2559 179/3780 180/4015 170/3505 
● Event rate and 95% CI 
(per 100 person-years) 
6.3 (5.4, 7.3) 4.7 (4.1, 5.5) 4.5 (3.9, 5.2) 4.9 (4.2, 5.6) 
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● Crude model HR (95% 
CI) 
1.38 (1.11, 1.71) Ref 0.94 (0.77, 1.16) 1.03 (0.84, 1.27) 
● Multivariable adjusted 
model HR (95% CI) 
1.33 (1.07, 1.66) Ref 0.95 (0.77, 1.17) 1.07 (0.87, 1.33) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.29 (1.04, 1.62) Ref 0.97 (0.79, 1.20) 1.11 (0.89, 1.38) 
Renal composite outcome     
● Events/person-years 13/2543 17/3762 34/3979 33/3467 
● Event rate and 95% CI 
(per 100 person-years) 
0.5 (0.3 0.9) 0.5 (0.3, 0.7) 0.9 (0.6, 1.2) 1.0 (0.7, 1.3) 
● Crude model HR (95% 
CI) 
1.19 (0.58, 2.46) Ref 1.89 (1.06, 3.38) 2.15 (1.20, 3.38) 
● Multivariable adjusted 
model HR (95% CI) 
1.26 (0.60, 2.61) Ref 1.91 (1.06, 3.43) 1.95 (1.08, 3.54) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.30 (0.62, 2.71) Ref 1.87 (1.04, 3.38) 1.87 (1.02, 3.43) 
Drug discontinuation     
Selvaraj S, et al. Systolic Blood Pressure in HFpEF   42 
 
● Events/person-years 274/2261 318/3412 315/3584 327/3046 
● Event rate and 95% CI 
(per 100 person-years) 
12.1 (10.8, 13.6) 9.3 (8.3, 10.4) 8.8 (7.9, 9.8) 10.7 (9.6, 12.0) 
● Crude model HR (95% 
CI) 
1.29 (1.10, 1.52) Ref 0.94 (0.81, 1.10) 1.14 (0.98, 1.33) 
● Multivariable adjusted 
model HR (95% CI) 
1.20 (1.02, 1.41) Ref 0.96 (0.82, 11.3) 1.09 (0.93, 1.28) 
● Multivariable adjusted 
model 2 HR (95% CI) 
1.21 (1.02, 1.43) Ref 0.96 (0.82, 1.12) 1.08 (0.92, 1.27) 
HR, hazard ratio; CI, confidence interval; HF, heart failure. 
Time-updated, mean achieved systolic blood pressure uses average SBP as a time-updated covariate, which is updated at each BP ascertainment to 
represent the average observed blood pressure up to that time point. 
Model 1 covariates include region, atrial fibrillation, creatinine, diabetes mellitus, New York Heart Association class, heart rate, sex, age, race, 
current smoking, number of anti-hypertensive medications, and treatment group.  
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TABLE 4. Valsartan-adjusted Change in Systolic Blood Pressure at the 4 Week Visit by Treatment Arm  






Treatment Effect of Sacubitril/valsartan vs. 
Valsartan 
 4-week Change in 
SBP (95% CI) 
4-week Change 
in SBP (95% CI) 
4-week Change in SBP (95% CI) P-value 
All Patients -1.8 (-2.4, -1.2) +3.4 (+2.8, +4.1) -5.2 (-6.0, -4.4) <0.001 
SBP < 120 mmHg +5.5 (+4.4, +6.6) +10.7 (+9.5, 
+11.9) 
-5.3 (-6.9, -3.6) <0.001 
120 mmHg ≤ SBP <129 mmHg 
 
+1.4 (+0.3, +2.5) +6.3 (+5.2, +7.4) -4.9 (-6.5, -3.3) <0.001 
130 mmHg ≤ SBP < 139 mmHg 
 
-3.8 (-4.9, -2.7) +1.3 (+0.1, +2.4) -5.1 (-6.7, -3.5) <0.001 
SBP ≥ 140 mmHg 
 
-8.5 (-9.6, -7.4) -3.1 (-4.3, -2.0) -5.4 (-7.0, -3.9) <0.001 
SBP, systolic blood pressure. 
Analyses adjust for baseline blood pressure. 
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TABLE 5. Relationship between Change in Systolic Blood Pressure and Changes in Quality of Life and Biomarkers from 
Baseline to the 16 and 48-Week Visit. 
 Total 
N 
Change in Parameter per 
10 mmHg Reduction in 
Systolic Blood Pressure 





P for treatment 
interaction 
Change in Parameter per 10 
mmHg Reduction in Systolic 
Blood Pressure from 
Baseline to the 48-Week 
Visit 
Fully-adjusted Model 
Beta-coefficient (95% CI)*^ 
P for treatment 
interaction 
Quality of Life      
• KCCQ-OSS (change in 
score) 
4507 +0.1 (-0.2, +0.4), p=0.40 0.10 +0.1 (-0.3, +0.3), p=0.92 0.30 
Biomarkers      
• NT-proBNP (% change) 3222 -3.8% (-5.4%, -2.2%), 
p<0.001 
0.75 -2.1% (-3.8%, -0.2%), 
p=0.027 
0.72 
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• High-sensitivity troponin 
T (% change) 
1205 +0.9% (-0.3%, +2.0%), 
p=0.13 
0.98 +1.0% (-0.4%, +2.4%), 
p=0.16 
0.98 
CI, confidence interval; KCCQ-OSS, Kansas City Cardiomyopathy Questionnaire Overall Summary Score. 
*Expressed as change in the parameter (KCCQ-OSS, NT-proBNP, or high-sensitivity troponin T) per 10 mmHg decrease in systolic blood 
pressure from baseline to the specified visit (16 or 48 week visit). All analyses controlled for and baseline blood pressure.  
^ Additionally adjusted for baseline covariates including region, atrial fibrillation, creatinine, diabetes mellitus, New York Heart Association class, 
heart rate, sex, age, race, current smoking, number of anti-hypertensive medications, and treatment group. 
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Table 6. Effect of Change in Systolic Blood Pressure on Treatment Effect of Sacubitril/valsartan  









Composite endpoint 0.87 (0.75, 1.01) 0.058 0.87 (0.75, 1.00) 0.056 
Recurrent HF hospitalization 0.85 (0.72, 1.00) 0.051 0.85 (0.72, 1.01) 0.059 
Renal composite outcome 0.50 (0.33, 0.77) 0.001 0.52 (0.34, 0.79) 0.002 
CI, confidence interval; HF, heart failure.  
*Adjusted for baseline systolic blood pressure and time-updated systolic blood pressure. 
 
 
